About SCI
SCI Pharmtech Inc., founded by Switzerland-based Siegfried Ltd. in 1987, is now a public company listed at Taiwan Stock Exchange.
Since 1989, SCI has satisfied worldwide customers with quality and cost-effective APIs, advanced intermediates, and custom products.
Our fully equipped research laboratories, pilot and production plants and experienced staff ensure timely development and cost effective production.
We work with pharmaceutical and specialty companies worldwide to develop key intermediates, APIs and custom products.
Our facility is FDA,EDQM and Taiwan TFDA inspected, designed for multi-purpose, full-scale manufacturing.
Company Mission
To be a well recognized partner for pharmaceutical products and chemical services by creating sustainable solutions to the industry.
Corporate Vision
For the health of human being, we contribute.
Corporate Values
Sustainability
Credibility
Innovation
永續Sustainability
信賴Credibility
創新Innovation
SCI History
-
1980
- Sep. 1987 Established by Siegfried Group (Switzerland) as an intermdeiate provider in Asia. Siegfried owned 80%
- Dec. 1989 Production commenced
-
1990
- Apr. 1996 Siegfried Group acquired 100% of shares
- Nov. 1999 ISO 14001 certified
-
2000
- Apr. 2001 Mercuries Group acquired 80% of shares
- Oct. 2001 ISO 9001 certified
- Apr. 2002 Company name changed to “SCI Pharmtech Inc”35 products commercialized
- Jan. 2004 Listed on Taiwan stock exchange market
- Jun. 2004 Inspected by Taiwan health authorities
- Nov. 2005 Inspected by US FDA 1ST
- Jun. 2008 Established Nanjing SCI Pharmtech Ltd in Nanjing, China
-
2010
- May 2010 OHSAS 18001 certified
- Nov. 2010 Inspected by EDQM 1ST
- Apr. 2012 Inspected by US FDA 2ND
- Sep. 2012 Inspected by KFDA 1ST
- Mar. 2013 Liquidated Nanjing SCI Pharmtech Ltd in Nanjing, China
- Jun. 2013 Established Yushan Pharmaceuticals, Inc.
- Dec. 2014 Inspected by US FDA 3RD
- Nov. 2016 Inspected by EDQM 2ND
- Sep. 2017 Inspected by US FDA 4TH
- Nov. 2017 Inspected by PMDA 1ST
- Oct. 2019 Rated perfect bonded warehouse by Taiwan customs, and keeps maintaining the status
- Nov. 2019 Inspected by US FDA 5TH
-
2020
- April. 2020 Visited by President Tsai, who instructed the formation of Pharmaceuticals Manufacturing Team
- August 2020 Signed a contract with Veolia Environment to establish Framosa Co,Ltd. with a 40% and 60% shareholding ratio to engage in circular economy activities for the purification and reuse of chemical solvents
- December 2020 At noon on December 20, an explosion occurred on the company's production line and caused a fire
- November 2021 Recapitalization of retained earnings of NT$ 33,290 thousand. Paid-in capital increased to NT$ 953,823,720
- November 2021 The board of directors has approved the capex of Guanyin Plant
- October 2021 For 15 consecutive years, it has been appraised as a premium bonded factory by the Taipei Customs Bureau of the Ministry of Finance
- December 2021 Partial area has resumed production, providing about 10% of production capacity
- March 2022 TFDA GMP site inspection
- September 2022 Signed a DBO contract with Framosa Co., Ltd. for the wastewater treatment facility of Guanyin Plant
- December 2022 The board of directors has approved the additional budget for the construction of Guanyin Plant
- July 2023 About 35% of production capacity has been restored
- August 2023 Recapitalization of retained earnings & employee bonus. Paid-in capital increased to NT$ 1,075,086,340
- November 2023 Issuance of common stock of NT$ 120,000 thousand. Paid-in capital increased to NT$ 1,195,086,340